Skip to main content

Deep Lens Closes $14M Series A Round to Advance Digital AI Pathology Platform

NEW YORK (360Dx) – Deep Lens said today that it has closed a $14 million Series A round to further expand its artificial intelligence and platform product development activities. It will also use the financing to scale its service, sales, and marketing organizations to support demand and growth for its approach to clinical trial recruitment.

The Series A closing comes three months after Columbus, Ohio-based Deep Lens completed a venture capital-led seed equity round, bringing its funding to date to $17.5 million.

Deep Lens Cofounder and CEO Dave Billiter said in statement that the Series A financing is further validation of the value of its approach to digital pathology "in delivering the right cancer diagnoses faster and accelerating oncology trial recruitment and timelines."

Northpond Ventures led the Series A funding round with participation from existing investors Rev1 Ventures, Sierra Ventures, and Tamarind-Hill Partners.

The company’s flagship technology, called VIPER, short for Virtual Imaging for Pathology Education and Research, combines artificial intelligence with advanced pathology workflows and enables peer-to-peer collaboration and patient identification for clinical trials.

By identifying eligible patients at the time of their diagnoses, VIPER can help fast-track trial enrollment and potentially shorten the duration of the trial, Deep Lens said.

This past year, the firm has integrated deep learning and made its platform available free of charge to pathology groups worldwide to identify patients at the time of diagnosis for available clinical trials.

In March, Deep Lens and Worldwide Clinical Trials, a contract research organization, announced a strategic alliance in oncology to combine the Deep Lens digital pathology platform and the CRO's expertise in clinical cancer research and global clinical trial operations.